Pfizer Inc. (NYSE:PFE) is Barnett & Company Inc.'s 5th Largest Position

Key Points

• Barnett & Company Inc. reduced its position in Pfizer Inc. by 8.3% during the first quarter, now holding 204,465 shares worth approximately $5.18 million.
• Pfizer recently announced a quarterly dividend of $0.43 per share, with a yield of 7.0%, and a payout ratio of 91.49%.
• The company's stock is currently rated as a "Hold" by analysts, with a consensus price target of $28.12.

Barnett & Company Inc. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 204,465 shares of the biopharmaceutical company's stock after selling 18,433 shares during the quarter. Pfizer comprises 4.3% of Barnett & Company Inc.'s investment portfolio, making the stock its 5th biggest position. Barnett & Company Inc.'s holdings in Pfizer were worth $5,181,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Clarity Asset Management Inc. bought a new stake in Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. North Capital Inc. bought a new stake in Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the 4th quarter worth approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. BMO Capital Markets decreased their price target on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Finally, TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Up 0.1%

Shares of NYSE PFE traded up $0.03 during mid-day trading on Monday, hitting $24.61. 38,065,234 shares of the stock traded hands, compared to its average volume of 46,565,748. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a market cap of $139.93 billion, a price-to-earnings ratio of 13.09, a PEG ratio of 0.88 and a beta of 0.52. The stock has a fifty day moving average price of $24.46 and a 200-day moving average price of $24.47.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the company posted $0.60 EPS. Pfizer's revenue was up 10.3% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.